Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours

NCT07446855 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07446855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 17, 2026
Completion date
March 29, 2030
Enrollment
180 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours